Almac confirm exhibition sponsorship of BOS Manchester 2020
Bio2Business is pleased to welcome Almac as an exhibitor sponsor at BOS Manchester 2020, which will take place on the 17th and 18th of November, 2020, at the Congress Centre Basel in Switzerland. The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally.
CARBOGEN AMCIS Confirm Gold Sponsorship at BOS Manchester 2020
Bio2Business is pleased to welcome CARBOGEN AMCIS as a Gold Sponsor at BOS Manchester 2020. CARBOGEN AMCIS experts will deliver a 15 minute presentation on the 18th November, 10.45-11.00 in the CMC Small Molecule Track and you can meet their delegates at booth number 33. Further details regarding the presentation theme will follow. CARBOGEN AMCIS, a member of the Dishman Group, provide drug development and commercialisation services to the pharmaceutical and biopharmaceutical industries, at all stages of drug development.
Solara Active Pharma Sciences Confirms Exhibition Sponsor Package at BOS Manchester 2020
Bio2Business is delighted to welcome Solara Active Pharma Sciences as an exhibitor at BOS Manchester 2020. Solara Active Pharma Sciences provides CDMO Services and is an API Manufacturer. With over 5 Manufacturing Sites and 2 R&D Centers, Solara offers a production range from a milligram to metric ton level. As a CDMO, Solara specializes in tech transfer, analytical development, route scouting, GMP Manufacturing and Commercial Supply.
AMRI, a global contract research and manufacturing organization, partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life. With locations in North America, Europe and Asia, AMRI's team combines scientific expertise and market-leading technology to provide a complete suite of solutions in Discovery, Development, Analytical Services, API Manufacturing and Drug Product. We've got it down to an exact science.
We care about the quality and success of your projects as if they were our own. No matter the size of your project or the complexity of the challenge, our experts pinpoint and execute the precise solution to hit your target. From molecule to molecule, batch to batch, your product will benefit from our ingenuity.
CARBOGEN AMCIS AG is a leading service provider, offering a portfolio of drug development and commercialization services to the pharmaceutical and biopharmaceutical industries at all stages of drug development. Our integrated services for Drug Substances (DS) and Drug Products (DP) provide innovative solutions to support timely and safe drug development. CARBOGEN AMCIS is also active in the marketing/sales and manufacture of Vitamin D analogues, Vitamin D, Cholesterol and lanolin related products for key markets as pharmaceutical, cosmetic, food, feed as well as industry applications.
Our flexible approach enables customers to benefit from tailored packages of work which balance their needs in terms of speed, cost and quality. CARBOGEN AMCIS also adapts their communication and reporting to match customer specific requirements and documentation. CARBOGEN AMCIS has been part of Dishman Carbogen Amcis Limited since 2006.
Quality is central to the CARBOGEN AMCIS business. We provide services for the development and manufacture of highly potent drug substances (APIs) and drug products applying state-of-the-art containment technologies.
CARBOGEN AMCIS offers services starting from laboratory scale for process research and development purposes up to large scale manufacturing. To support the API development process through all stages, a variety of high containment analytical and purification capabilities complements the chemistry service portfolio. In addition to our process research and manufacturing services for the fast supply of highly potent APIs, CARBOGEN AMCIS offers conjugation services for Antibody Drug Conjugates (ADCs) as well as formulation and fill-and-finish services for drug products.
CARBOGEN AMCIS mission is to provide innovative solutions for drug development and supply to the pharmaceutical and biopharmaceutical industries that enable customers to bring new generation medicines to the market.
Quay Pharmaceuticals is experienced in providing a comprehensive out-sourcing service for formulation and analytical development with subsequent clinical trials and commercial manufacturing for pharmaceutical and
biotechnology companies world-wide.
Working as a dedicated, pro-active part of your team we apply strong project management and technical expertise to take products quickly and cost effectively from late stage pre clinical through to the end of phase III clinical trials and Commercial Manufacturing.
Quay Pharma has vast expertise in dosage form design and development and with Prof Mike Rubinstein, Prof John Collett (CSO) and Prof Larry Gifford Quay Pharma has built a reputation for specialising in the formulation of API's that exhibit poor solubility and bio-availability and those which require modified or controlled release. This has resulted in many Quay Pharma clients successfully licensing products on to large, global pharmaceutical companies.
From MHRA and FDA licensed inspected facilities the
- pre-clinical to commercial formulation development
- novel drug delivery system design
- analytical - transfer or method development and validation
- live biotherapeutic drug delivery
- ICH stability testing
- clinical trial manufacture in class 100,000 (ISO8) environment
- conventional, coated and controlled
release tablets and capsules
- powder, liquid / semi-solid fill capsules
- liquid /semi solid formulations (e.g. nasal and oral solutions, creams)
- pellets / spheroids and extrudates
- medical devices
- commercial manufacturing
- packing and labelling
- full QC testing services
- QP certification and importation of investigational medicinal products from outside the EU.
- CMC's and regulatory document support for product registration
Quay Pharma holds a Manufacturing Authorisation from the MHRA for the manufacture and testing of investigational medicinal products (IMPÃ¢â‚¬â„¢s), as specified by the EU Clinical Trials Directive (2001/20/EC) and also possesses a "Specials" licence.
For further information contact:
Head of Business Development
Telephone: +44 (0) 1244 837 004
Sterling Pharma Solutions Ltd (stand 9)
Sterling Pharma Solutions has over 50 years' experience serving the global pharmaceutical industry, (large, small and virtual), from our North-East England base. Offering state-of-the-art facilities, a wide variety of chemistry capabilities and experienced people, we have a proven track record in the supply of chemistry and analytical services across the entire product lifecycle. We offer full grams to tonnes service and support products from pre-clinical through to commercial supply.
Our world-class safety and quality standards are globally recognised and demonstrated through successful MHRA and FDA inspections and a CIA Diamond Award for Safety over the last ten years. This enables challenging
chemistries, (fluorinations, cryogenics, high-pressure reductions and carbonylations), to be carried out safely and successfully, along with the capacity and capability to handle highly potent molecules and controlled drugs.
We pride ourselves on our customer focus and service approach, offering flexible, tailored solutions to meet our clients' needs and requirements.
Mike Smallwood; firstname.lastname@example.org
Business Development Director
Sterling Pharma Solutions Ltd
Northunberland, NE23 7QG
Almac Group, an established contract development and manufacturing organisation, provides the most unique range of integrated drug development services available to the pharmaceutical & biotech industry.
A privately owned organisation that has grown over 50 years, we now employ over 5,000 high skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with 17 global facilities across the UK, Ireland, USA and Asia.
Our quality, innovation and efficiency are testimony to over 600 companies worldwide who trust Almac for their Chemical, Pharmaceutical and Clinical Development needs.
Addressing the increasing pressure for Biopharma companies to bring their clinical candidates through their pipeline faster, more efficiently and at a lower cost, Almac provides an integrated CMC service, bridging the gap between drug substance and drug product development.
As an established provider of both drug substance (advanced intermediates and Active Pharmaceutical Ingredients - small molecules and peptides) and drug product development services, and by offering these within an integrated package, our client partners are assured of scientific continuity from a dedicated project team, resulting in significant savings in time and costs.
Integrated teams within Chemical and Pharmaceutical Development work closely to fully understand the physicochemical properties of the API to ensure the optimum chemical entity is available for the manufacture of clinical supplies.
Whether your requirements are for First in Human supplies or later phase development, manufacture or registration batches, Almac have access to a wide range of innovative technologies for potent and non-potent, solid oral dose products.
Having integrated chemical and pharmaceutical development operations, facilitates optimal communication and knowledge transfer on projects. Our clients leverage this combined offering, exploiting the Almac advantage of a single partner approach. Smoothing transition through the drug development process and commercialisation saves time, transfers and other uncertainties inherent in a multi-supplier process.
anaRIC is an independent, Belgian-based CRO supporting biotech & pharma companies with top quality, tailor-made analytical services.
We help expedite your drug development process by applying our expert knowledge for a wide array of pharmaceutical products, including small molecules (NCEs & generics), cell-based medicinal products & biologics (NBEs & biosimilars) e.g. example mAbs, mAb variants, ADCs, recombinant proteins, peptides, vaccines & oligonucleotides.
Working closely with our customers, we understand how in-depth product understanding and drug development expertise are critical attributes for success.
Obtaining a comprehensive analytical insight is a continuous process and its scope evolves with each new step during development, across non-GMP and GMP activities.
We are ready to tackle your analytical challenges as a reliable & flexible extension of your own team.
Our scientifically-driven, proactive approach and continuous involvement create a powerful learning platform.
anaRIC ensures you have the right data available at the right time!
Fareva is a top 5 CDMO globally with 40 production sites around the world focusing on drug substance and drug product development and manufacturing.
Highlights of Fareva Corporate:
- 5th largest CDMO in world by revenue
- 1.6 billion revenue in 2018
- 40 Production Sites and more than 12,000 Employees
Highlights of Fareva API:
- cGMP small molecule manufacturing for clinical programs and commercial production
- First and only company in the world to receive SafeBridge Certification to handle high potent drug substance and drug product at the same facility
- Milling and Micronization
- Aseptic processing of APIs (crystallization, micronization and packaging of API)
- Programs range from 1kg to 50MT annually
- World class process chemistry team
- High potent and cytotoxic APIs
- Conventional APIs (not potent)
- PSD and Polymorph control
- Global registrations (100+ DMFs in US, Canada, Japan, Europe)
- Sterilization of API by Ethylene Oxide
- Experience across a broad range of chemical classes - more than 200 different molecules
Highlights of Fareva Formulation and Drug Product Manufacturing:
- Ophtalmic forms (BFS, conventional and preservative-free bottles)
- Injectables (freeze-dried vials, ampoules and pre-filled syringes)
- Aerosols (conventional and bag on valve) and sprays (mechanical, preservative free)
- Suspensions, solutions and gels (bottles, sachets and stick-packs)
- Granules and powders (sticks packs, sachets, bottle); tablets (uncoated, coated, sugar coated) and capsules (blisters and bottles) with cytoxic expertise
-Creams, ointments, gel and jellies (single dose, sachets, alu, polyfoil or plastic tubes); sterile ointments and gels (polyfoil or aluminium tubes)
- Suppositories & ovulas
- Food supplements; herbal tea (grade pharma or not)
- Narcotics management and expertise (3 sites)
LAXAI is a fully integrated contract research and development organization that delivers solutions in drug discovery, early formulation development, chemical process development, and GMP manufacturing for innovator pharmaceutical, biotech, and animal health companies globally. Over the years, our focus has been on providing highly efficient scientific solutions, which has enabled us to partner on more than 20 integrated drug discovery programs and multiple medicinal chemistry focussed FTE collaborations. As a result, we have delivered clinical candidates and technology platforms in Oncology, Rheumatoid Arthritis, and Antibacterial respectively. Further, owing to our strength in chemistry and our experience in solving complex problems, we have been engaged on a number of chemical process development and GMP manufacturing projects by innovator pharmaceutical companies. This experience, spanning more than a decade, has enabled us to develop deep expertise in custom NCEs, and custom manufactured advanced intermediates and fine chemicals.
LGC is a global leader in the life sciences sector. We provide a comprehensive range of reference materials, proficiency testing schemes, genomics reagents and instrumentation, research and measurement services.
Our Drug Development Solutions business helps pharma, biotech, CROs/CDMOs, medical device and consumer healthcare companies provide assurance and high quality data to support their discovery, development and manufacture activities.
With cGMP labs in the UK, Germany and US and a track record of success in regulatory audits, including the FDA, we support the regulatory Chemistry, Manufacturing and Control (CMC) compliance of your drug substance and drug product through the complex challenges faced in drug development, solving issues at all stages of manufacture. Our CMC services cover a broad range of physical and chemical method development and testing capabilities with Centres of Excellence in Material Science and Impurity and Contamination Analysis.
In addition, with one of the world’s largest bioanalytical centres, recognised for leadership in science and technology, LGC has comprehensive capabilities for pharmacokinetics, immunogenicity and biomarkers that span LC-MS/MS through to immunoassay, cell and molecular biology. We routinely solve difficult method development challenges and, as your development progresses from discovery through to GLP preclinical and to GCP clinical trials, we have the capacity, rapid turnaround and logistics needed to support the largest, most complex protocols.
For a full range of services offered visit www.lgcgroup.com/dds
LGC. Science for a safer world.
Minakem is a leading supplier of pharmaceutical fine chemicals.
With R&D, Quality Control & Assurance, production and regulatory affairs services, we offer a complete range of CDMO services from development to production of APIs, HPAPIs, cGMP advanced intermediates, Generic APIs and catalogue/custom building blocks, from grams to multi tons (Total capacity = 290 m3).
We have a proven track record in our capability to take projects from early stage through to commercial manufacture.
In trusted long-term partnerships, we enable pharmaceutical and biotechnological companies to support and speed-up the development and production of innovative treatments of the highest quality to their patients globally.
We can offer number of technologies including highly potent handling (up to class 6), solid chemistry, industrial preparative chromatography, flow chemistry expertise coupled with photochemistry and electrochemistry.
We operate three FDA approved sites in France and Belgium.
Novasep provides flexible contract development & manufacturing (CDMO) solutions for Small Molecule APIs & Biopharmaceuticals to innovators. We offer a wide range of flexible cGMP manufacturing assets on multiple sites with an outstanding regulatory track record.
We are a world leader in a number of technologies including industrial chromatography (batch and continuous), hazardous & cryogenic chemistry, HPAPIs, ADCs & Viral Vectors.
Novasep has recently invested over >100mEuro to expand its commercial manufacturing footprint including:
- ADCs: A new 11mEuro¬ bioconjugation unit in Le Mans, France.
- Viral Vectors: Senrise-IV, a new 27mEuro facility for AAV, Adenovirus, Lentiviral vectors, HSV... in Seneffe, Belgium.
- Fill & Finish: Senefill, a new 10mEuro facility for aseptic Fill & Finish operations for viral vectors, viruses, plasmids and other biologics in Seneffe, Belgium.
Have a look at our website to learn more about our services: www.novasep.com
- And to contact us: email@example.com
Solara Active Pharma Sciences, a leading Contract organization from India, offers drug discovery, development, manufacturing and commercialization services to advance their partners ongoing research, from Concept to Commercialization. Our experienced pool of scientists, are backed by 5 manufacturing sites and 2 dedicated R&D centres. While our manufacturing sites have been successfully audited by the USFDA for 22 times, we have also been audited by other regulatory agencies like EDQM, AGES (Austria), KFDA (Korea), EU-GMP (Danish), MHRA, Cofepris (Mexico) and PMDA (Japan). Our facilities are also certified with ISO 14001:2004 and ISO 45001:2018.
Solara’s scientists have impeccable experience of over three decades, enabling Solara to provide Contract Research and Manufacturing Services (CRAMS) from discovery to late phase commercial manufacturing in Full Time Equivalent and Fee for Service models respectively. Our capabilities include route scouting, process development and optimization, tech transfer, salt / polymorph screening and GMP manufacturing.
Angelini Fine Chemicals is one of the major Italian CDMOs serving branded pharmaceutical industries. Located in the industrial outskirts of Aprilia (Southern Rome Area, Italy), Angelini Fine Chemicals is at the forefront of development and manufacturing of Adv. IMs., APIs and HPAPIs of relevance to the pharmaceutical market.
With 70.000 m2 cGMP manufacturing facility and cutting-edge R&D labs, Angelini Fine Chemicals is housing a wide reaction technology portfolio and scale-up capabilities to advancing your chemical development programs – from early clinical lots up to commercial manufacturing, from 1-1000+kg up to multi-tons scale. Our continuous programs of investments in R&D and novel chemical technologies (such as Flow Chemistry and High Containment API), make Angelini Fine Chemicals an attractive and trustworthy CDMO partner for Custom Synthesis for over 50 years.
Arcinova is a Contract Development and Manufacturing Organisation that helps pharmaceutical and biotechnology companies across the globe develop life changing medicines. We employ a multidisciplinary approach to drug development by combining the disciplines of chemistry, biology and bioinformatics. All our services are delivered from our 15,000m2 facility in the North of England.
We leverage our decades of experience as a key research and development centre for Sanofi and Covance to deliver high quality end-to-end solutions. Our mission is to deliver best-in-class technology services in the fields of contract research, development and small-scale manufacturing to overcome project challenges and increase efficiency.
CALIXAR has developed unique technologies coupled with a state-of-the-art research platform enabling the production of novel therapeutic targets of the highest quality and covering all therapeutic areas. In particular, CALIXAR implements new approaches to isolate native full-length membrane therapeutic targets and develops its own pipeline of medically relevant targets. It also uses its patented technology platform for other companies that need to identify, express, extract, purify and stabilize native membrane proteins (GPCRs, ion channels, receptors, transporters and viral targets). CALIXAR’s approach provides pharmaceutical companies with the opportunity to work with high-quality and reliable targets or antigens, compatible with all applications. This includes developing antibodies and/or discovering primary leads through Structure-Based Drug Design (X-ray and cryo-EM) or High Throughput Screening assays. The CALIXAR platform also enables new vaccine formulations.
For more information on CALIXAR, its pipeline, its products and its services, please visit www.calixar.com or follow us on LinkedIn.
CordenPharma is your full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Drug Products and associated Packaging Services. Through a network of cGMP facilities across Europe and the US organized under five technology platforms - Peptides, Lipids & Carbohydrates - Injectables - Highly Potent & Oncology - Small Molecules - Antibiotics - CordenPharma experts translate complex ideas, processes and projects at any stage of development into high-value products.
Peptides, Lipids & Carbohydrates:
- Synthetic Peptide API Production
- Synthetic Lipids